How China’s investment in health care AI helps it deal with the coronavirus crisis
- China named its first team of national AI champions in 2017, tasking them to develop the technology for uses including health care
- The developments since have proven useful today, in light of the ongoing coronavirus outbreak
When China announced its initial team of national artificial intelligence (AI) champions in 2017, Tencent Holdings was tasked with leading the development of computer vision for medical diagnosis.
Soon after, the company launched an AI medical imaging platform capable of diagnosing a broad list of illnesses, and a cloud-based ecosystem for sharing and collaboration between domestic health care AI companies.
The same year, an intelligent robot developed by iFlyTek passed China’s written national qualification exam for doctors, in what was hailed as a game changer for the country’s strained health care system.
“A lot of technologies have played a very important role in containing the outbreak,” said Zhong Zhenshan, International Data Corporation (IDC) vice-president of emerging technology research. “In return, this will largely enrich the application scenarios of emerging technologies in China and will promote the development of the entire market.”
Diagnosis is the focus of most AI initiatives in China’s health care sector, given the “sizeable opportunity” presented by the large number of patients and the data they generate, according to the Post’s report.
Such applications are proving useful at hospitals, which are beset with plenty of patients and more people anxious to know if they could be infected with the virus that causes Covid-19.
A prediction model developed by Ping An Technology, for instance, is helping health care authorities in Chongqing and Shenzhen predict outbreaks ahead of time with accuracy rates of more than 90 per cent, according to the report.
“Throughout the coronavirus outbreak, it has been demonstrated that online medical consultation is an efficient, convenient method that allows [suspected] patients to avoid catching infectious diseases,” said Ping An Good Doctor’s chairman and chief executive Wang Tao earlier this month.
Purchase the China AI Report 2020 brought to you by SCMP Research and enjoy a 20% discount (original price US$400). This 60-page all new intelligence report gives you first-hand insights and analysis into the latest industry developments and intelligence about China AI. Get exclusive access to our webinars for continuous learning, and interact with China AI executives in live Q&A. Offer valid until 31 March 2020.